Literature DB >> 16185815

Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status.

Jennifer A Rusiecki1, Theodore R Holford, Shelia H Zahm, Tongzhang Zheng.   

Abstract

BACKGROUND: We investigated risk factor patterns for subtypes of breast cancer characterized by joint estrogen receptor (ER) and progesterone receptor (PR) status in a hospital-based case-control study.
METHODS: ER and PR tumor status were determined immunohisotchemically. Risk factors of interest were entered into a multiple polychotomous logistic regression model simultaneously; odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Using this model, cases in the four tumor subtypes (ER+PR+, ER-PR-, ER+PR-, ER-PR+) were compared simultaneously to controls. A Wald test for heterogeneity across the four subtypes was conducted, as well as a case-case comparison between the two most biologically disparate subtypes, ER+PR+ and ER-PR-.
RESULTS: The receptor status distribution was as follows: 33% ER+PR+, 34% ER-PR-, 20% ER+PR-, and 13% ER-PR+. Among 317 cases and 401 controls, we found significant heterogeneity across the four tumor subtypes for older age at first full-term pregnancy (p=0.04) and post-menopausal status (p=0.04). For older age at first full-term pregnancy, an elevated risk was found for the ER+PR- subtype (OR=2.5; 95% CI: 1.2-5.1). For post-menopausal status, elevated risks were found for both the ER+PR+ (OR=2.4; 95% CI: 1.1-4.9) and ER+PR- (OR=7.2; 95% CI: 2.4-21.7) subtypes. From the case-case comparisons, we found that cases, who had consumed alcohol for more than 1 year were 3.4 times more likely to have ER+PR+ tumors than ER-PR- tumors (95% CI: 1.4-8.4).
CONCLUSIONS: Certain breast cancer risk factors may vary by ER and PR status, and joint ER/PR status should be taken into account in future studies of risk factor estimates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185815     DOI: 10.1016/j.cdp.2005.07.004

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  23 in total

1.  Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer.

Authors:  A Mansour; M Nabil; R Ali-Labib; H Said; F Annos
Journal:  Med Oncol       Date:  2011-12-08       Impact factor: 3.064

Review 2.  Genetic susceptibility to breast cancer.

Authors:  Nasim Mavaddat; Antonis C Antoniou; Douglas F Easton; Montserrat Garcia-Closas
Journal:  Mol Oncol       Date:  2010-05-21       Impact factor: 6.603

3.  Active smoking and risk of Luminal and Basal-like breast cancer subtypes in the Carolina Breast Cancer Study.

Authors:  Eboneé N Butler; Chiu-Kit Tse; Mary Elizabeth Bell; Kathleen Conway; Andrew F Olshan; Melissa A Troester
Journal:  Cancer Causes Control       Date:  2016-05-06       Impact factor: 2.506

4.  Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics.

Authors:  Lusine Yaghjyan; Graham A Colditz; Laura C Collins; Stuart J Schnitt; Bernard Rosner; Celine Vachon; Rulla M Tamimi
Journal:  J Natl Cancer Inst       Date:  2011-07-27       Impact factor: 13.506

5.  Methylation status and overexpression of COX-2 in Tunisian patients with ductal invasive breast carcinoma.

Authors:  Sondes Karray-Chouayekh; Fatma Trifa; Abdelmajid Khabir; Noureddine Boujelbene; Tahia Sellami-Boudawara; Jamel Daoud; Mounir Frikha; Ali Gargouri; Raja Mokdad-Gargouri
Journal:  Tumour Biol       Date:  2010-12-10

6.  Familial relative risks for breast cancer by pathological subtype: a population-based cohort study.

Authors:  Nasim Mavaddat; Paul D Pharoah; Fiona Blows; Kristy E Driver; Elena Provenzano; Deborah Thompson; Robert J Macinnis; Mitul Shah; Douglas F Easton; Antonis C Antoniou
Journal:  Breast Cancer Res       Date:  2010-02-10       Impact factor: 6.466

7.  BP1 Homeoprotein Enhances Metastatic Potential in ER-negative Breast Cancer.

Authors:  Yebo Fu; Yi Lian; Kyung Soon Kim; Lei Zhang; A Katharine Hindle; Fred Brody; Robert S Siegel; Timothy A McCaffrey; Sidney W Fu
Journal:  J Cancer       Date:  2010-06-24       Impact factor: 4.207

8.  Incorporating tumour pathology information into breast cancer risk prediction algorithms.

Authors:  Nasim Mavaddat; Timothy R Rebbeck; Sunil R Lakhani; Douglas F Easton; Antonis C Antoniou
Journal:  Breast Cancer Res       Date:  2010-05-18       Impact factor: 6.466

9.  Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.

Authors:  Sondes Karray-Chouayekh; Fatma Trifa; Abdelmajid Khabir; Nouredine Boujelbane; Tahia Sellami-Boudawara; Jamel Daoud; Mounir Frikha; Rachid Jlidi; Ali Gargouri; Raja Mokdad-Gargouri
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-06       Impact factor: 4.553

10.  Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.

Authors:  Sondes Karray-Chouayekh; Fatma Trifa; Abdelmajid Khabir; Nouredine Boujelbane; Tahia Sellami-Boudawara; Jamel Daoud; Mounir Frikha; Ali Gargouri; Raja Mokdad-Gargouri
Journal:  J Biomed Biotechnol       Date:  2009-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.